Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ: MDGL) announced participation in two upcoming virtual investor conferences. The 42nd Annual Goldman Sachs Global Healthcare Conference fireside chat is scheduled for June 10, 2021, at 9:40 a.m. ET, followed by a JMP Securities Life Sciences Conference fireside chat on June 16, 2021, at 3:30 p.m. ET. Both presentations will be webcast live and available for 90 days replay.

Madrigal focuses on developing therapeutics for cardio-metabolic and fatty liver diseases, with its lead candidate, resmetirom, currently in two Phase 3 studies for NASH and NAFLD.

WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences:

42nd Annual Goldman Sachs Global Healthcare Conference
Fireside chat at 9:40 a.m. ET on Thursday, June 10, 2021

JMP Securities Life Sciences Conference
Fireside chat at 3:30 pm ET on Wednesday, June 16, 2021

The presentation will be webcast live and can be accessed in the Investor Relations section of the Madrigal website and will be available for replay for 90 days. https://www.madrigalpharma.com/newsroom/presentations/

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits across a broad spectrum of NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) patients.
For more information, visit www.madrigalpharma.com.

Investor Contact: Alex Howarth, Madrigal Pharmaceuticals, Inc. IR@madrigalpharma.com Media Contact:

Mike Beyer, Sam Brown Inc. mikebeyer@sambrown.com 312 961 2502

FAQ

What conferences is Madrigal Pharmaceuticals participating in June 2021?

Madrigal Pharmaceuticals will participate in the 42nd Annual Goldman Sachs Global Healthcare Conference on June 10, 2021, and the JMP Securities Life Sciences Conference on June 16, 2021.

When will the Goldman Sachs Global Healthcare Conference fireside chat take place?

The Goldman Sachs Global Healthcare Conference fireside chat is scheduled for June 10, 2021, at 9:40 a.m. ET.

What is Madrigal Pharmaceuticals' lead candidate for NASH?

Madrigal's lead candidate for NASH is resmetirom, a first-in-class, orally administered thyroid hormone receptor (THR)-β selective agonist.

How can I access the webcasts of Madrigal Pharmaceuticals' presentations?

The webcasts of Madrigal Pharmaceuticals' presentations can be accessed in the Investor Relations section of their website and will be available for replay for 90 days.

What diseases is Madrigal Pharmaceuticals targeting with its therapeutics?

Madrigal Pharmaceuticals is targeting cardio-metabolic diseases and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).